MeSH tree: D03.132.225
To the known risk factors for cardiovascular disease—high blood pressure, high cholesterol, diabetes, overweight and obesity, smoking, and physical inactivity—a new one has to be added, clonal hematopoiesis. This condition ...
Aug 30, 2024
0
138
In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organization Conference (ESOC 2024), anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke ...
May 15, 2024
0
49
Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, according to late breaking research ...
Aug 25, 2023
0
34
Colchicine, a widely available gout medication, has received FDA approval to be used in low dose to prevent cardiovascular events in patients with proven coronary disease.
Jun 29, 2023
0
111
An exploratory analysis of the LoDoCo2 (Low-Dose Colchicine 2) randomized, controlled, double-blind trial found that daily therapy with a low dose of colchicine was associated with lower incidences of both total knee replacement ...
May 29, 2023
0
96
Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to $190.49 in 2011. Out-of-pocket ...
May 8, 2023
0
77
Researchers at National Jewish Health have found that a subset of children suffering recurring fevers as a result of long COVID-19 have benefited from a daily medication treatment commonly used for gout and periodic fever ...
Apr 25, 2023
0
59
New evidence released today from a study of 31,245 patients already taking statin therapy indicates that inflammation may be a more powerful predictor of risk of future cardiovascular events—such as heart attack and stroke—than ...
Mar 6, 2023
0
867
A randomized trial in nearly 4,000 outpatients with COVID-19 has found no benefit of treatment with aspirin or colchicine. The late breaking research was presented in a Hot Line session on 29 August at ESC Congress 2022.
Aug 30, 2022
0
42
The antidepressant drug fluvoxamine and the gout drug colchicine are not recommended for patients with mild or moderate COVID-19 because there is currently insufficient evidence that they improve important outcomes for patients, ...
Jul 13, 2022
0
82
